Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
Hosted on MSN5d
A promising schizophrenia drug showed mixed results. What does that mean for patients?Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the ...
For the past 70 years, schizophrenia treatments all targeted the same chemical: dopamine. While that works for some, it ...
Intra-Cellular Therapies said on Tuesday its drug to prevent relapses in schizophrenia patients met the main goal of a late-stage trial.
Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...
Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the research Some people who took a new schizophrenia drug for a year ...
A Promising Schizophrenia Drug Showed Mixed Results. What Does That Mean for Patients? Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many ...
Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...
Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback